|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: XPR1 |
Gene summary for XPR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | XPR1 | Gene ID | 9213 |
| Gene name | xenotropic and polytropic retrovirus receptor 1 | |
| Gene Alias | IBGC6 | |
| Cytomap | 1q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9UBH6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9213 | XPR1 | CCI_2 | Human | Cervix | CC | 2.22e-22 | 3.07e+00 | 0.5249 |
| 9213 | XPR1 | CCI_3 | Human | Cervix | CC | 1.63e-17 | 1.27e+00 | 0.516 |
| 9213 | XPR1 | sample1 | Human | Cervix | CC | 1.25e-03 | 4.15e-01 | 0.0959 |
| 9213 | XPR1 | T1 | Human | Cervix | CC | 5.02e-04 | 3.37e-01 | 0.0918 |
| 9213 | XPR1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.00e-07 | -4.09e-01 | 0.0155 |
| 9213 | XPR1 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.66e-04 | -2.69e-01 | -0.1464 |
| 9213 | XPR1 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.07e-03 | -2.64e-01 | -0.1001 |
| 9213 | XPR1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.27e-03 | -3.72e-01 | 0.096 |
| 9213 | XPR1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.33e-09 | -4.32e-01 | 0.0674 |
| 9213 | XPR1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.99e-08 | -3.14e-01 | 0.294 |
| 9213 | XPR1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.54e-03 | -3.04e-01 | 0.3859 |
| 9213 | XPR1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.32e-02 | -4.86e-01 | 0.2585 |
| 9213 | XPR1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.28e-15 | -4.94e-01 | 0.3005 |
| 9213 | XPR1 | F007 | Human | Colorectum | FAP | 1.65e-03 | -3.28e-01 | 0.1176 |
| 9213 | XPR1 | A001-C-207 | Human | Colorectum | FAP | 1.54e-03 | -2.53e-01 | 0.1278 |
| 9213 | XPR1 | A015-C-203 | Human | Colorectum | FAP | 2.48e-22 | -4.02e-01 | -0.1294 |
| 9213 | XPR1 | A015-C-204 | Human | Colorectum | FAP | 4.86e-05 | -3.40e-01 | -0.0228 |
| 9213 | XPR1 | A014-C-040 | Human | Colorectum | FAP | 8.52e-03 | -4.11e-01 | -0.1184 |
| 9213 | XPR1 | A002-C-201 | Human | Colorectum | FAP | 7.32e-14 | -3.60e-01 | 0.0324 |
| 9213 | XPR1 | A002-C-203 | Human | Colorectum | FAP | 8.64e-06 | -2.62e-01 | 0.2786 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004440334 | Thyroid | ATC | biological process involved in symbiotic interaction | 153/6293 | 290/18723 | 1.12e-11 | 4.12e-10 | 153 |
| GO:0071496210 | Thyroid | ATC | cellular response to external stimulus | 165/6293 | 320/18723 | 2.01e-11 | 7.23e-10 | 165 |
| GO:005170134 | Thyroid | ATC | biological process involved in interaction with host | 112/6293 | 203/18723 | 1.93e-10 | 5.76e-09 | 112 |
| GO:003166927 | Thyroid | ATC | cellular response to nutrient levels | 112/6293 | 215/18723 | 1.57e-08 | 3.20e-07 | 112 |
| GO:003166827 | Thyroid | ATC | cellular response to extracellular stimulus | 125/6293 | 246/18723 | 1.65e-08 | 3.31e-07 | 125 |
| GO:005212633 | Thyroid | ATC | movement in host environment | 94/6293 | 175/18723 | 3.20e-08 | 6.00e-07 | 94 |
| GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
| GO:004259424 | Thyroid | ATC | response to starvation | 103/6293 | 197/18723 | 4.59e-08 | 8.31e-07 | 103 |
| GO:000926724 | Thyroid | ATC | cellular response to starvation | 85/6293 | 156/18723 | 6.14e-08 | 1.09e-06 | 85 |
| GO:0031667210 | Thyroid | ATC | response to nutrient levels | 212/6293 | 474/18723 | 2.37e-07 | 3.70e-06 | 212 |
| GO:004440933 | Thyroid | ATC | entry into host | 76/6293 | 151/18723 | 1.54e-05 | 1.43e-04 | 76 |
| GO:004671833 | Thyroid | ATC | viral entry into host cell | 72/6293 | 144/18723 | 3.38e-05 | 2.80e-04 | 72 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| XPR1 | SNV | Missense_Mutation | c.101N>G | p.Asp34Gly | p.D34G | Q9UBH6 | protein_coding | deleterious(0.02) | benign(0.3) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| XPR1 | SNV | Missense_Mutation | c.2077G>A | p.Glu693Lys | p.E693K | Q9UBH6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.257) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| XPR1 | SNV | Missense_Mutation | novel | c.926N>A | p.Ser309Asn | p.S309N | Q9UBH6 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AC-A7VC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| XPR1 | SNV | Missense_Mutation | novel | c.1376G>A | p.Arg459His | p.R459H | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| XPR1 | SNV | Missense_Mutation | novel | c.1005N>A | p.Phe335Leu | p.F335L | Q9UBH6 | protein_coding | tolerated(1) | benign(0) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| XPR1 | SNV | Missense_Mutation | c.1832G>A | p.Arg611His | p.R611H | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A2FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | goserelin | SD | |
| XPR1 | SNV | Missense_Mutation | rs751223491 | c.1342C>T | p.Arg448Trp | p.R448W | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
| XPR1 | SNV | Missense_Mutation | c.817C>T | p.Arg273Trp | p.R273W | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| XPR1 | SNV | Missense_Mutation | c.2077N>A | p.Glu693Lys | p.E693K | Q9UBH6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.257) | TCGA-EK-A3GN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| XPR1 | SNV | Missense_Mutation | c.1798N>A | p.Glu600Lys | p.E600K | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |